Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bayer, Johnson and...

    Bayer, Johnson and Johnson's heart drug Xarelto fails trial to widen use

    Written by Ruby Khatun Khatun Published On 2018-08-28T09:45:01+05:30  |  Updated On 17 Aug 2021 6:37 AM GMT

    FRANKFURT: Bayer and Johnson and Johnson's campaign to widen the market for its heart drug Xarelto hit a snag on Sunday when a study for a potential new patient subgroup failed to show a statistically reliant benefit.


    The blockbuster clot prevention drug could not be shown to reduce the rate of dangerous blood clots in a certain group of high-risk patients after discharge from a hospital, the New England Journal of Medicine reported.


    Participants in the so-called Mariner study had previously been admitted to hospital for a range of conditions that are associated with a higher risk of venous thromboembolism, such as heart failure, acute respiratory disease, ischemic stroke or infections.


    Bayer reported 3.3 billion euros ($3.77 billion) in Xarelto revenues last year, mainly from stroke prevention in the elderly, and expects annual sales to rise above 5 billion euros.


    A Bayer spokesman said that the latest results, also presented at the European Society of Cardiology congress in Munich, did not change its peak sales estimate or have any implications for other conditions that Xarelto is approved for.


    It is a reversal of fortunes for Bayer, which in July won approval for additional Xarelto use in the potentially lucrative market for atherosclerosis patients.


    Bayer has the marketing rights for the drug outside the United States while partner J&J sells Xarelto in the U.S., with Bayer being eligible for royalties on U.S. sales of 20-30 percent.



    (Reporting by Ludwig Burger; Editing by Kirsten Donovan)
    acute respiratory disease atherosclerosis Bayer clot prevention drug heart drug heart failure infections ischemic stroke Johnson and Johnson New England Journal of Medicine venous thromboembolism Xarelto 
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      X